Japan prospective multicenter study for the optimization of the COVID-19 vaccination based on the immune response and safety profile in inflammatory bowel disease patients

Japan prospective multicenter study for the optimization of the COVID-19 vaccination based on the immune response and safety profile in inflammatory bowel disease patients - J-COMBAT trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043545

Enrollment

600

Registered

2021-03-08

Start date

2021-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease (ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with inflammatory bowel disease (600 cases) or healthy persons (150 persons) who are willing vaccination of COVID-19.

Exclusion criteria

Exclusion criteria: 1) The patients with active COVID-19 2) The patients with inflammatory bowel disease or persons who are not vaccinated. 3) The patients with inflammatory bowel disease or persons who are less than 16 years old.

Design outcomes

Primary

Measure	Time frame
The immune responses and safety profiles of COVID-19 vaccination in patients with inflammatory bowel disease.	—

Countries

Japan

Contacts

Public ContactKenji Watanabe

Hyogo College of Medicine Center for Inflammatory Bowel Disease, Division of Internal Medicine

kenjiw1779@gmail.com0798-45-6663

Outcome results